Innovation Digest – November 2022 Vol. 1

One of my earliest experiences with health care was as a family member and caregiver. The costs we incurred exceeded medical care and had lasting impact on quality of life, our family’s health and well-being, and on our work and education. Measuring the costs of disease burden on family and caregivers is vital to ensuring we fully value the impact of preventive care, early diagnostics, precision therapies, and new innovations that promote and sustain health. If we only focus on the surgery, the hospital stay, the device or the pill, we’ve really missed the true cost to families and to society. It’s good to see more attention to patient and family costs. But, if we’ve known about these factors for decades, why is it taking so long to act? What will you do to create change? How can I help you make it happen?

In this issue:

  • Finding Equity in Value:  Racial and Health Equity Implications of U.S. HTA Processes
  • Expanding The Resources Available To Caregivers To Care For Themselves, Their Patients, And Their Families
  • CDER official reflects on a decade of patient-focused drug development
  • Support family caregivers to improve and diversify clinical trials
  • Health Benefits In 2022: Premiums Remain Steady, Many Employers Report Limited Provider Networks For Behavioral Health
Back to Viewpoint